secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-07-30T20:05:37+00:00
Accession:  0001070081-26-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q2 net income $83.5M, raises FY product revenue guidance to $850-950M
--------------------------------------------------------------------------------

- Q2 total revenue $361M (product $239M) includes $50M Novartis milestone; net income $83.5M vs net loss $64.8M YoY.
- FY 2026 product revenue guidance raised to $850-950M (from $750-850M); total revenue guidance raised to $1.18-1.28B.
- Sephience Q2 revenue $151M (+21% QoQ); 1,647 patients on therapy; Translarna $42.2M, Emflaza $24.6M, Evrysdi royalty $71.1M.
- Issued $550M senior convertible notes due 2031 at 0% coupon, 40% conversion premium; repurchased majority of 1.5% notes due 2026. Cash $2.23B.
- Pipeline: PTC303 (MSH3) targeting Huntington's, clinic entry 2027; PTC612 (NLRP3) Phase 1 initiated; vatiquinone PROVE-FA study Q3 2026; votoplam PIVOT-HD 24-month results showed 52% disease slowing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/0001070081-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer